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Thyroid status in humans is an important factor in the regulation of lipoprotein metabolism. There are several data on 
hypothyroidism in the adult population, but less information is available about congenital hypothyroidism. Since lipid 
metabolism at birth is substantially different from that of adults, it is not likely that the same abnormalities that occur in adult 
hypothyroidism are also present when this is diagnosed at early life. We studied 16 subjects with congenital hypothyroidism, 
seven at the time of diagnosis and also after normalization of thyroid hormone levels over a period of 2.0 _+ 1.0 months of 
substitution therapy with L-thyroxine (5.9 -+ 1.2 ~g/kg/d)  and nine already on L-thyroxine therapy for a period of 4.7 -+ 3.2 
months. Thirty-nine apparently healthy subjects matched for age were selected as controls. In all subjects, total cholesterol 
(CHO), triglycerides (TG), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol (HDL-C), 
apolipoproteins (apo) A-I and B, lipoprotein(a) [Lp(a}] thyrotropin (TSH), (LDL-C), total and free thyroxine (T4), and 
triiodothyronine (T3) were determined. CHO, HDL-C, and apo A-I levels were significantly higher in patients at the time of 
diagnosis than in controls (respectively, P = .0079, .0007, and .0004}, whereas TG, LDL-C, apo B, and Lp(a) levels were not 
significantly different. During L-thyroxine substitution therapy in these subjects, HDL-C and apo A-I levels significantly 
decreased (respectively, by a mean of -36.2% and -24.4%}, with similar behavior in all subjects. To verify if these lipoprotein 
changes were due to L-thyroxine substitution therapy or to physiological modifications with time, we remeasured lipoprotein 
parameters also in 10 normal subjects approximately 2 months later than the first measurement, but no significant change was 
found. Moreover, all subjects with congenital hypothyroidism on L-thyroxine substitution therapy did not show any significant 
difference in lipoprotein profile in comparison to age-matched controls. Our data document that infants with congenital 
hypothyroidism mainly show high HDL-C levels, and that L-thyroxine substitution therapy completely restores a normal lipid 
profile. Since HDL plays a major role in newborns and in the first days of life, we suggest that thyroid hormones modulate the 
physiological development of lipoprotein metabolism after birth, and that the lack of thyroid hormones does not permit 
complete evolution of newborn lipid patterns toward an adult profile. 
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T HYROID STATUS in humans is an important factor in the regulation of lipoprotein metabolism. In the 
adult population, hypothyroidism is associated with an 
increase of total (CHO) and low-density lipoprotein (LDL) 
cholesterol (LDL-C), as well as triglyceride (TG) levels, v3 
Also, high-density lipoprotein (HDL) cholesterol (HDL-C) 
seems to be affected by hypothyroidism. 4,5 Furthermore, a 
role in the regulation of lipoprotein(a) [Lp(a)] levels by 
thyroid hormones was recently suggested. 6,7These abnor- 
malities are the consequence of multiple alterations due to 
the lack of thyroid hormones: impairment of lipolytic 
enzymes, receptor pathways, or lipoprotein synthesis. TM
However, substitution therapy improves lipoprotein metabo- 
lism parameters and restores a normal ipid profile. 9,12-I5 
Although there are several studies on acquired hypothyroid- 
ism of adults, less data are available on congenital hypothy- 
roidism. I6-19 It is not likely that the same abnormalities that 
occur in adult hypothyroidism are also present when this is 
diagnosed after birth. In the first weeks of life, lipoproteins 
are present in plasma concentrations and involved in 
metabolic roles substantially different from those of adults: 
in particular, HDLs, which in adults have the function of 
reverse transport of cholesterol, may be used as a source of 
cholesterol from the peripheral tissues. 20-22 Moreover, in 
many countries, including Italy, congenital hypothyroidism 
is currently screened in newborns, and early institution of 
substitution therapy avoids the clinical effects of the lack of 
thyroid hormones. 23,24 
In this study, we evaluated lipid, lipoprotein, apolipopro- 
tein, and Lp(a) levels in a group of subjects with congenital 
hypothyroidism as compared with age-matched healthy 
controls, and the effects of substitution therapy with L- 
thyroxine. 
SUBJECTS AND METHODS 
Subjects 
The total population consisted of 16 patients (eight males and 
eight females) aged 1 year or less with congenital hypothyroidism 
who were part of a larger group of outpatients evaluated by the 
Department of Pediatrics of the University of Palermo. Seven of 
them (four males and three females aged 0.5 to 3 months) found 
over a 15-month period were studied at the time of diagnosis 
(before any treatment) and also after a period of 2.0 _+ 1.0 months 
of substitution therapy with L-thyroxine (5.9 ~ 1.2 ~g/kg/d), when 
thyroid hormones were restored to the normal range. Nine subjects 
(four males and five females) on L-thyroxine therapy (mean dose, 
4.5 _+ 1.2 Izg/kg/d) for a period of 4.7 --2- 3.2 months were included 
in the study as well. In all patients, congenital hypothyroidism was 
diagnosed by neonatal screening on a blood spot; diagnosis was 
further confirmed by clinical evaluation and measurement of
thyrotropin (TSH) and thyroid hormone levels on a blood sample. 
The type of hypothyroidism (aplasia or hypoplasia of thyroid 
gland) was evaluated by thyroid scan with 99Tc.25 Thirty-nine 
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apparently healthy subjects (19 males and 20 females) matched for 
age were selected as controls. 
Methods 
In all subjects, a blood sample was collected in the morning in 
Na-EDTA tubes as long as possible after a fast (at least 5 to 6 
hours). In every sample, CHO and TG levels were measured 
enzymatically, 2627 HDL-C was assayed after precipitation f apoli- 
poprotein (apo) B-containing lipoproteins by phosphotungstic 
acid/magnesium chloride and enzymatic determination f choles- 
terol, 28 apos A-I and B were determined byan immunonephelomet- 
ric method, 29 LDL-C level was calculated by a modification of the 
Friedewald formula, ie, LDL-C = [CHO - (TG/5 - HDL-C)] - 
(Lp(a) • 0.3), 3° and Lp(a), TSH, total (T4) and free thyroxine (FT4), 
and triiodothyronine (T3) levels were measured by radioimmunoas- 
say. 31-33 Quality control of plasma lipid and apolipoprotein assays 
was performed as previously described. 34 
StatisticaI Analysis 
Statistical analysis was performed using Student's t test for 
paired or independent data when suitable. The log of TG and 
Lp(a) rather than raw data were used in all statistical nalyses. 35
RESULTS 
Clinical Characteristics 
Clinical characteristics of all subjects are shown in Table 
1. All patients tudied at the time of diagnosis were affected 
by aplasia of the thyroid gland, and aplasia was also the 
prominent defect in all subjects on L-thyroxine therapy. 
Despite substitution therapy, not all subjects in the group 
on L-thyroxine therapy, which included both patients re- 
cently treated (time of therapy, 2.0 +_ 1.0 months) and 
patients treated for a longer time (time of therapy, 4.7 -- 3.2 
months), were in a completely euthyroid state. However, 
thyroid hormone levels were markedly improved in compari- 
son to levels in untreated subjects. There was an obvious 
difference in the mean age between untreated subjects at 
the time of diagnosis and subjects on L-thyroxine therapy; 
for this reason, controls aged 0.5 to 12 months were not 
considered all together but were divided into two groups 
matched for age with the two groups of hypothyroid 
individuals. 
Table 1. Clinical Characteristics of All Subjects 
At Time of On L-Thyroxine 
Characteristic Diagnosis Therapy Controls 
No. of subjects 7 16 39 
Age (mo) 
Mean -+ SD 1.2 -+ 0.7 5.3 -+ 3.0 3.5 +- 1.7 
Range 0.5-3 2-12 0.5-12 
Males/females 4/3 8/8 19/20 
Aplasia/hypoplasia 7/0 13/3 / 
Body weight (kg) 3.6 -+ 1.0 7.4 _+ 2.2 7.0 _+ 2,4 
TSH (#IU/mL) 
Mean +- SD 504.7 + 237.3 12.6 +_ 24.4 1.9 -+ 0.9 
Range 240-996 0.5-100 0.75-4.2 
T4 (p,g/dL) 1.2 -+ 1,3 12.7 -+ 2.8 13.4 _+ 3.1 
FT4 (ng/dL) 0.6 -+ 0.5 1.7 -+ 0.6 1.8 -+ 0.3 
T3 (ng/mL) 0.7 -+ 0.2 1,7 -+ 1.5 1.2 -+ 0.4 
L-Thyroxine dose (#g/ 
kg/d) - -  5.1 +- 1.5 - -  
Time of therapy (mo) - -  3.7 + 2,6 - -  
Table 2. Lipid, Lipoprotein, and Apolipoprotein Levels in Seven 
Untreated Subjects With Congenital Hypothyroidism at Time of 
Diagnosis and in 17 Age-Matched Controls 
Hypothyroid 
Parameter Patients P Controls 
Age 
Mean + SD 1.2 _+ 0.7 ,855 1.3 -+ 0.4 
Range 0.5-3 0.5-2 
CHO 
Mean _+ SD 187.1 +_ 61.3 ,0079 136.0 _+ 26.1 
Range 120-315 93-188 
TG 
Mean _+ SD 163.7 + 79.0 ,3164 122.4 _+ 68.5 
Range 75-300 49-330 
HDL-C 
Mean _+ SD 79.5 +_ 16.8 .0007 49.5 + 17.1 
Range 62-115 21-76 
LDL-C 
Mean _+ SD 70.9 _+ 40,1 .4727 62.0 +_ 20.3 
Range 20-135 15-96 
Apo A-I 
Mean _+ SD 200.8 _+ 18,6 .0004 148.0 _+ 30.9 
Range 179-226 78-186 
Apo B 
Mean _+ SD 73,6 _+ 22,8 .8701 72.1 + 18.1 
Range 46-116 45-100 
Lp(a) 
Mean _+ SD 2.8 _+ 1.8 .2976 5.5 _+ 5.2 
Range 1.4-5.4 1.2-13.7 
NOTE. Age is expressed in months and lipid parameters in mg/dL. 
Plasma Lipids in Untreated Patients and Effects of 
Substitution Therapy 
Lipid, lipoprotein, and apolipoprotein levels in seven 
untreated subjects with congenital hypothyroidism at the 
time of diagnosis and in 17 age-matched controls are shown 
in Table 2. CHO, HDL-C, and apo A-I levels were 
significantly higher in patients in comparison to controls 
(respectively, P = .0079, .0007, and .0004), whereas TG, 
LDL-C, apo B, and Lp(a) levels were not different. In these 
seven subjects, after normalization of thyroid hormone 
levels (T4, FT4, and T3) over a period of treatment with 
L-thyroxine, during which a strong reduction of TSH levels 
was also observed (from 504.7 _ 237.3 to 23.8 --- 35.1 txU/ 
L), a significant decrease of HDL-C and apo A-I levels was 
found (respectively, by -36.2% and -24.4%, P = .0000 
and .0001; Table 3). Individual data before and during 
L-thyroxine substitution therapy are shown in Fig 1. It is 
possible to note that all patients presented a reduction of 
HDL-C and apo A-I levels. To verify if these lipoprotein 
changes were due to L-thyroxine substitution therapy or to 
physiological modifications with time, we remeasured lipo- 
protein parameters also in 10 normal subjects approxi- 
mately 2 months later than the first measurement, but no 
significant change was found (data not shown). In Table 4, 
lipid, lipoprotein, and apolipoprotein levels in all subjects 
with congenital hypothyroidism on L-thyroxine substitution 
therapy and in age-matched controls are shown. We pooled 
subjects recently treated with L-thyroxine with patients with 
congenital hypothyroidism on substitution therapy for sev- 
eral months to evaluate the effects of replacement therapy 
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Table 3. Lipid, Lipoprotein, and Apolipoprotein Levels in Seven 
Subjects With Congenital Hypothyroidism at Time of Diagnosis 
and During L-Thyroxine Substitution 
At Time of 
Parameter Diagnosis P During 
TSH 504.7 _+ 237.3 .0001 23,8 ± 15,1 
(240-996) (0.5-100) 
CHO 187.1 ± 61.3 .1852 146.0 _+ 34.1 
TG 163.7 + 79.0 .6410 148.8 ± 46.4 
HDL-C 79.5 -+ 16.8 .0000 50.7 ± 13.7 
LDL-C 70.9 _+ 40.1 .7720 65.5 _+ 24.2 
Apo A-I 200.8 -+ 18.6 .0001 151.8 ± 23.5 
Apo B 73.6 -+ 22.8 .6439 68.6 - 17.0 
Lp(a) 2.8 _+ 1.8 .6671 3,2 _+ 2.1 
NOTE. TSH is expressed in p, lU/mL, and lipid parameters in mg/dL. 
Parenthetical values for TSH are ranges. 
on lipoprotein parameters in relation to a normal lipopro- 
tein profile, but no significant difference was found. 
DISCUSSION 
The main finding of this study is that congenital hypothy- 
roidism leads to a selective impairment of the HDL system. 
Although there are a number of studies evaluating relation- 
ships between thyroid function and lipids in adults] -~7 
fewer data are available on congenital hypothyroidism, 18,19 
a disorder with a prevalence of one in 4,000 births, mostly 
due to thyroid dysgenesis (aplasia or hypoplasia). 25 In 
adults, hypothyroidism represents one of the most common 
causes of secondary hyperlipidemia. 36 In particular, both 
very-low-density lipoprotein (VLDL) and LDL metabolism 
are affected. Impaired VLDL transport and fractional 
catabolic rates were found, and apo B and E receptor 
activity was documented to be greatly reduced; also, enzy- 
matic activities involved in lipid metabolism, like lipopro- 
tein and hepatic lipase (HL) or lecithin cholesterol acyltrans- 
ferase (L-CAT), may be low. 8-12,I4,15 Therefore, in 
hypothyroidism plasma levels of LDL and VLDL fractions 
and apo B levels are considerably increased, but all these 
alterations are completely reversible after L-thyroxine sub- 
stitution therapy. 12-]5 Moreover, several studies investigated 
relationships between thyroid hormones and HDL metabo- 
lism. HDL-C was generally reported to be increased in 
hypothyroidism, with a selective levation of HDL2 .4'5'9'11'I4 
Hepatic apo A-I synthesis should be sensitive to thyroid 
status, but in hypothyroid rats a defective clearance of HDL 
from plasma was documented. 37,38 Also, activity of choles- 
terol ester transfer protein, which is involved in the ex- 
change of esters of cholesterol between lipoproteins, was 
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Table 4. Lipid, Lipoprotein, and Apolipoprotein Levels in 16 Subjects 
With Congenital Hypothyroidism on L-Thyroxine 
Substitution-Therapy and in 22 Age-Matched Controls 
Hypothyroid 
Parameter Patients P Controls 
Age 5.3 ± 3.0 .7635 5.0 + 2.8 
(2-12) (2-12) 
CHO 151.1 ± 29.8 .5926 145.3 ± 29.0 
"I-G 148.6 ± 78.7 .4806 130.6 ± 59.5 
HDL-C 48.8 -+ 13.5 .4790 45.5 ± 15.5 
LDL-C 72.5 ± 28.4 .9419 73.7 + 25.2 
Apo A-I 144.0 ± 18.6 .1089 131.1 -+ 33.3 
Apo B 81.5 ± 22.7 .7262 84.1 ± 22.3 
Lp(a) 7.3 ± 9.0 .5937 8,2 -+ 12.6 
NOTE. Age is expressed in months, and lipid parameters in mg/dL. 
Parenthetical values for age are ranges. 
found to be decreased in hypothyroidism2 ~ These mecha- 
nisms might contribute to the increase of HDL-C levels in 
adult hypothyroidism. However, in newborns and in the 
early life, lipoprotein metabolism is consistently different 
from that of adults. HDL is the main lipoprotein class in 
cord blood, and significant differences occur in plasma 
concentrations and distributions of apolipoproteins in neo- 
nates as compared with adults. 2° At birth, a distinct HDL 
fraction enriched in apo E could be detected. 21This particle 
might represent an additional source of cholesterol for 
peripheral tissues via the apo (B, E) receptor, while both 
VLDL and LDL concentrations are  low.  20-22 After the onset 
of enteral feeding, several factors, including VLDL synthe- 
sis, lipolytic and esterification enzymes, and lipid-exchange 
activities, may be related to modification of the lipid 
profile. 39 We designed this study to verify which lipid 
abnormalities might occur in congenital hypothyroidism. 
The lipoprotein profile rapidly changes during the first 
weeks of life4°; for this reason, we always compared 
hypothyroid subjects with strictly age-matched normal con- 
trols. We found that untreated subjects howed a significant 
increase of total and HDL-C and apo A-! levels, and that 
normalization of thyroid hormones by L-thyroxine substitu- 
tion therapy was followed by a significant decrease of 
HDL-C and apo A-I levels. In the same period (~2 
months), a group of age-matched normal controls did not 
show significant modification of lipoprotein profile (data 
not shown), and this suggests that changes observed in 
hypothyroid subjects were due to L-thyroxine substitution 
therapy and normalization of thyroid status. It is otherwise 
remarkable that there was a reduction in HDL-C and apo 
A-I levels in all subjects (Fig 1), which supports the 
metabolic relevance of these data. In contrast, other param- 
eters like LDL-C or apo B, which are usually affected by 
hypothyroidism in adults, 1,2,6,13 were not increased at the 
time of diagnosis and did not significantly change during 
treatment. Also, Tenenbaum et a118 previously documented 
that large-size HDL subfractions were increased in congeni- 
tal hypothyroidism before treatment and decreased signifi- 
cantly after L-thyroxine therapy, but did not find any 
modification in LDL apo B levels. They also found that 
lipoprotein lipase and HL activities were significantly re- 
duced in hypothyroid infants as compared with adult 
reference values, but only HL increased after therapy. In 
contrast, Moorjani et al, 19 as stated by the same investiga- 
tors, surprisingly did not observe any lipid abnormalities in
hypothyroid neonates, but did not provide any data about 
substitution therapy. In the present study, we also evalu- 
ated Lp(a) levels. Plasma concentrations of this lipoprotein 
particle are low at birth and increase during the first years 
of life. 41 Even if Lp(a) levels are mostly genetically deter- 
mined, 42 some data seem to document that thyroid status 
should be able to modulate them due to the effects on the 
apo (B, E) receptor, but this is still being debated. 6,7 
However, we were unable to demonstrate any influence of 
congenital hypothyroidism, aswell as substitution therapy, 
on Lp(a) levels in our patients. When we evaluated lipid, 
lipoprotein, and apolipoprotein parameters in a group of 
infants with congenital hypothyroidism on treatment with 
L-thyroxine, we observed that even without achievement of
a complete euthyroid status in all subjects, they did not 
show any difference in comparison to age-matched con- 
trois. These data suggest that although congenital hypothy- 
roidism markedly affects lipoprotein metabolism, L-thyrox- 
ine substitution therapy is able not only to produce a 
reduction of impaired parameters but also to completely 
restore the lipoprotein profile within the normal range, and 
that at this age, subclinical hypothyroidism could affect 
lipoprotein metabolism less than in adults. 1236 Therefore, 
thyroid hormones seem to be important in the physiological 
development of lipoprotein metabolism after birth. 39 This 
could be due to the modulation of the apo (B, E) receptor, 8 
which in early life should mainly be reflected in the HDL 
system. Alternatively, other factors found to be impaired in 
hypothyroidism, particularly cholesterol ester transfer pro- 
tein activity, 1~ might contribute to increase HDL, which repre- 
sents the main lipoprotein particle in the first weeks of life. 
In conclusion, our data document hat infants with 
congenital hypothyroidism ainly show high HDL-C and 
apo A-I levels, without any modifications of TG, LDL-C, 
apo B, or Lp(a) levels, and that L-thyroxine substitution 
therapy is able to restore a normal ipid profile. Since HDL 
plays a major role in newborns and in the first days of life, 
we suggest that thyroid hormones modulate the physiologi- 
cal development of lipoprotein metabolism after birth, and 
that the lack of thyroid hormones does not permit complete 
evolution of the newborn lipid pattern toward the adult 
profile. 
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